• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    2/14/24 1:43:55 PM ET
    $LIFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LIFE alert in real time by email
    SC 13G/A 1 atyr13ga.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

     

    aTyr Pharma, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

    002120202

    (CUSIP Number)

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 002120202

     

    1.Names of Reporting Persons.

    Laurence W. Lytton

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization USA

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 585,013

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 585,013
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 585,013

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 1.0%

     

    12.Type of Reporting Person (See Instructions) IN

     2 
    CUSIP No. 002120202

    Item 1.

     

    (a)Name of Issuer

    aTyr Pharma, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    10240 Sorrento Valley, Suite 300, San Diego, CA 92121

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Laurence W. Lytton

    (b)The principal business office of the Filers is located at:

    467 Central Park West
    New York, NY 10025

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to shares of Common Stock, par value $0.001 per share of the Issuer (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 002120202
     3 
    CUSIP No. 002120202
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page.

     

    The percentages reported in this Schedule 13G are based on 58,560,061 shares of Common Stock outstanding as of November 3, 2023, as reported in the Form 10-Q filed by the Issuer on November 9, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     4 
    CUSIP No. 002120202

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

    /s/ Laurence W. Lytton

    Laurence W. Lytton

     

     

     

    Get the next $LIFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    7/5/2023Outperform → Perform
    Oppenheimer
    11/11/2021$18.00 → $11.00Buy
    HC Wainwright & Co.
    11/11/2021$18.00 → $11.00Action List Buy
    HC Wainwright & Co.
    10/12/2021$22.00Outperform
    RBC Capital
    9/21/2021$19.00Overweight
    Piper Sandler
    9/14/2021$20.00 → $21.00Buy
    Roth Capital
    9/14/2021$14.00 → $20.00Outperform
    Oppenheimer
    9/13/2021$13.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/6/24 8:26:55 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 4:21:12 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 8:38:39 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"

      SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from "LIFE" to "ATYR." Effective at the market open on June 5, 2024, the Company's common stock will trade on the Nasdaq Capital Market under the new symbol "ATYR." "As we advance our lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis and prepare for potential commercialization, the "ATYR" ticker symbol is a strong reflec

      6/3/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 9,400 shares of aTyr's common stock, each with an exercise price of $1.86 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 22, 2024, the effective date of the grants. These stock awards were granted as an inducement material

      5/24/24 4:00:00 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

      SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. "These findings further demonstrate the unique way in which efzofitimod is modulating myeloid cells to confer the anti-inflammatory benefits we have seen in patients with pulmonary sarcoidosis, a major form o

      5/15/24 7:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Denyes Nancy bought $9,276 worth of shares (5,000 units at $1.86), increasing direct ownership by 29% to 22,267 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/6/24 8:26:55 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coughlin Timothy bought $87,500 worth of shares (50,000 units at $1.75) (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 4:21:12 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Broadfoot Jill Marie bought $8,950 worth of shares (5,000 units at $1.79), increasing direct ownership by 22% to 27,960 units (SEC Form 4)

      4 - aTYR PHARMA INC (0001339970) (Issuer)

      6/3/24 8:38:39 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • aTyr Pharma downgraded by Oppenheimer

      Oppenheimer downgraded aTyr Pharma from Outperform to Perform

      7/5/23 7:41:57 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Buy and set a new price target of $11.00 from $18.00 previously

      11/11/21 6:10:41 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Action List Buy and set a new price target of $11.00 from $18.00 previously

      11/11/21 6:10:41 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    SEC Filings

    See more
    • aTyr Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

      8-K - aTYR PHARMA INC (0001339970) (Filer)

      5/29/24 4:03:07 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by aTyr Pharma Inc.

      10-Q - aTYR PHARMA INC (0001339970) (Filer)

      5/2/24 4:07:23 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - aTYR PHARMA INC (0001339970) (Filer)

      5/2/24 4:04:01 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/14/24 1:43:55 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/13/24 4:30:17 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

      SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

      2/9/24 8:35:54 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LIFE
    Leadership Updates

    Live Leadership Updates

    See more
    • aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

      SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

      1/18/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

      SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives. "We are delighted to welcome Danielle to aTyr at a pivotal time in the company's journey as we expand our team to support our next phase of growth," said Sanjay S.

      12/24/21 8:02:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

      NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

      11/2/21 9:00:00 AM ET
      $AMGN
      $APVO
      $BCTX
      $BMY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $LIFE
    Financials

    Live finance-specific insights

    See more
    • aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

      Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

      3/14/24 4:00:00 PM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

      SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

      2/28/24 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

      SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

      3/2/23 8:00:00 AM ET
      $LIFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care